Cargando…

ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway

BACKGROUND: ER-α36, a novel ER-α66 variant, has been demonstrated to promote tamoxifen resistance in breast cancer cells. However, the role and mechanisms of ER-α36 in cisplatin resistance of breast cancer cells remain unclear. This study investigates the expression and role of ER-α36 in cisplatin r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Linlin, Zou, Jiao, Zhao, Yuanyin, Jiang, Xiaomei, Wang, Yang, Wang, Xiangwei, Chen, Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6019204/ https://www.ncbi.nlm.nih.gov/pubmed/29940998 http://dx.doi.org/10.1186/s13046-018-0798-z

Ejemplares similares

ERα36 as a Potential Therapeutic Target for Tamoxifen-Resistant Breast Cancer Cell Line Through EGFR/ERK Signaling Pathway
por: Li, Guangliang, et al.
Publicado: (2020)

Curcumin increases breast cancer cell sensitivity to cisplatin by decreasing FEN1 expression
por: Zou, Jiao, et al.
Publicado: (2018)

Concomitant high expression of ERα36, EGFR and HER2 is associated with aggressive behaviors of papillary thyroid carcinomas
por: Dai, Yu-Jie, et al.
Publicado: (2017)

Disruption of the ER-α36-EGFR/HER2 Positive Regulatory Loops Restores Tamoxifen Sensitivity in Tamoxifen Resistance Breast Cancer Cells
por: Yin, Li, et al.
Publicado: (2014)

ER-α36, a Novel Variant of ER-α, Mediates Estrogen-Stimulated Proliferation of Endometrial Carcinoma Cells via the PKCδ/ERK Pathway
por: Tong, Jing-Shan, et al.
Publicado: (2010)

A Positive Feedback Loop of ER-α36/EGFR Promotes Malignant Growth of ER-negative Breast Cancer Cells
por: Zhang, XianTian, et al.
Publicado: (2010)

ER-α36, a Variant of ER-α, Promotes Tamoxifen Agonist Action in Endometrial Cancer Cells via the MAPK/ERK and PI3K/Akt Pathways
por: Lin, Sheng-Li, et al.
Publicado: (2010)

ER-α36-mediated gastric cancer cell proliferation via the c-Src pathway
por: WANG, XUMING, et al.
Publicado: (2013)

Huaier polysaccharide inhibits the stem-like characteristics of ERα-36(high) triple negative breast cancer cells via inactivation of the ERα-36 signaling pathway
por: Hu, Baoquan, et al.
Publicado: (2019)

Cyanidin-3-o-glucoside directly binds to ERα36 and inhibits EGFR-positive triple-negative breast cancer
por: Wang, Li, et al.
Publicado: (2016)

Involvement of the Akt signaling pathway in ER-α36/GRP94-mediated signaling in gastric cancer
por: FU, ZHENGQI, et al.
Publicado: (2014)

Deciphering of a Putative GPER Recognition Domain in ERα and ERα36
por: Acramel, Alexandre, et al.
Publicado: (2022)

Carvacrol: An In Silico Approach of a Candidate Drug on HER2, PI3Kα, mTOR, hER-α, PR, and EGFR Receptors in the Breast Cancer
por: Herrera-Calderon, Oscar, et al.
Publicado: (2020)

The Role of ERα36 in Development and Tumor Malignancy
por: Thiebaut, Charlène, et al.
Publicado: (2020)

Long noncoding RNA MYLK-AS1 promotes growth and invasion of hepatocellular carcinoma through the EGFR/HER2-ERK1/2 signaling pathway
por: Liu, Juan, et al.
Publicado: (2020)

ERα-36 regulates progesterone receptor activity in breast cancer
por: Konan, Henri-Philippe, et al.
Publicado: (2020)

Down‐regulation of ER‐α36 mRNA in serum exosomes of the patients with hepatocellular carcinoma
por: Huang, Hui, et al.
Publicado: (2020)

EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy
por: Evans, A H, et al.
Publicado: (2010)

ER-α36-Mediated Rapid Estrogen Signaling Positively Regulates ER-Positive Breast Cancer Stem/Progenitor Cells
por: Deng, Hao, et al.
Publicado: (2014)

Estrogen receptor variant ER‐α36 promotes tamoxifen agonist activity in glioblastoma cells
por: Qu, Chao, et al.
Publicado: (2019)

The molecular mechanisms underlying the ERα-36-mediated signaling in breast cancer
por: Omarjee, S, et al.
Publicado: (2017)

Dual Epigenetic Regulation of ERα36 Expression in Breast Cancer Cells
por: Thiebaut, Charlène, et al.
Publicado: (2019)

Expression of ERβ, ERα and Her-2 and distribution of molecular subtypes in Uygur and Han patients with breast cancer
por: GUO, LIYING, et al.
Publicado: (2014)

From ERα66 to ERα36: a generic method for validating a prognosis marker of breast tumor progression
por: Chamard-Jovenin, Clémence, et al.
Publicado: (2015)

Chaperone gp96 mediates ER-α36 cell membrane expression
por: Hou, Junwei, et al.
Publicado: (2015)

Enhancement of Sensitivity to Tamoxifen by Berberine in Breast Cancer Cells by Inhibiting ER-α36 Expression
por: Pan, Xiaohua, et al.
Publicado: (2022)

Effects of 17β-estradiol and tamoxifen on gastric cancer cell proliferation and apoptosis and ER-α36 expression
por: Wang, Xuming, et al.
Publicado: (2017)

A novel variant of ER-alpha, ER-alpha36 mediates testosterone-stimulated ERK and Akt activation in endometrial cancer Hec1A cells
por: Lin, Sheng-Li, et al.
Publicado: (2009)

Pinin facilitated proliferation and metastasis of colorectal cancer through activating EGFR/ERK signaling pathway
por: Wei, Zhigang, et al.
Publicado: (2016)

ER-α36: a novel biomarker and potential therapeutic target in breast cancer
por: Su, Xingyun, et al.
Publicado: (2014)

Jab1 is a target of EGFR signaling in ERα-negative breast cancer
por: Wang, Jiaxu, et al.
Publicado: (2008)

Novel interactions between ERα-36 and STAT3 mediate breast cancer cell migration
por: Xiang, Yuan, et al.
Publicado: (2019)

Morphine promotes microglial activation by upregulating the EGFR/ERK signaling pathway
por: Yang, Yaqiong, et al.
Publicado: (2021)

ER-α36 Promotes the Malignant Progression of Cervical Cancer Mediated by Estrogen via HMGA2
por: Wang, Chunyan, et al.
Publicado: (2021)

Computational modelling of cancerous mutations in the EGFR/ERK signalling pathway
por: Orton, Richard J, et al.
Publicado: (2009)

ERα36-High Cancer-Associated Fibroblasts as an Unfavorable Factor in Triple-Negative Breast Cancer
por: Nagel, Anna, et al.
Publicado: (2022)

Protein tyrosine phosphatase SHP-1 sensitizes EGFR/HER-2 positive breast cancer cells to trastuzumab through modulating phosphorylation of EGFR and HER-2
por: Wu, Yifen, et al.
Publicado: (2015)

Estrogen Receptor (ER)-α36 Is Involved in Estrogen- and Tamoxifen-Induced Neuroprotective Effects in Ischemic Stroke Models
por: Zou, Wei, et al.
Publicado: (2015)

Tamoxifen enhances stemness and promotes metastasis of ERα36(+) breast cancer by upregulating ALDH1A1 in cancer cells
por: Wang, Qiang, et al.
Publicado: (2018)

Apigenin Inhibits Growth of Breast Cancer Cells: The Role of ERα and HER2/neu
por: Scherbakov, A. M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_q36abep2bnmss5ma00llf7qdoa